New Drug Application Submitted for ALS Drug

Article

Edaravone previously granted Orphan Drug Designation by the FDA for amyotrophic lateral sclerosis.

A New Drug Application (NDA) was recently submitted to the FDA for edaravone (MCI-186) in the treatment of amyotrophic lateral sclerosis (ALS).

The NDA submission is Mitsubishi Tanabe Pharma Corporation’s (MTPC) first step in accelerating its US business activities as part of their Medium-Term Management Plan 16-20: Open up the Future, the company noted in a press release.

Thus far, MTPC has established MT Pharma America, Inc to commercialize approved drug products in the United States as a part of their management plan, with future goals to expand its product line by collaborating with partners.

“There is an urgent need for new treatment approaches that may affect the course of this devastating disorder,” said Lucie Bruijn, PhD, MBA, Chief Scientist at The ALS Association. “The ALS Association is encouraged by the efforts of Mitsubishi Tanabe Pharma to make this drug available to people living with ALS in the US.”

In 2015, edaravone was approved to treat ALS in Japan and South Korea and was also granted Orphan Drug Designation by the FDA and European Commission.

Related Videos
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
Physician and kidneys
Image credit: gamjai - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.